This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2019 Oct;7(10):902-906.

doi: 10.1016/j.jchf.2019.05.013. Epub 2019 Sep 11.

Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure

Milton Packer¹

Affiliations

Affiliation

¹ Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas; Imperial College, London, United Kingdom. Electronic address: milton.packer@baylorhealth.edu.

PMID: 31521684
DOI: 10.1016/j.jchf.2019.05.013

Free article

Review

Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure

Milton Packer. JACC Heart Fail. 2019 Oct.

Free article

. 2019 Oct;7(10):902-906.

doi: 10.1016/j.jchf.2019.05.013. Epub 2019 Sep 11.

Author

Milton Packer¹

Affiliation

¹ Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas; Imperial College, London, United Kingdom. Electronic address: milton.packer@baylorhealth.edu.

PMID: 31521684
DOI: 10.1016/j.jchf.2019.05.013

No abstract available

Keywords: implantable cardioverter-defibrillator; neurohormonal antagonists; sudden death.

PubMed Disclaimer

Similar articles

ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.
DeVore AD, Al-Khatib SM. DeVore AD, et al. JACC Heart Fail. 2019 Oct;7(10):907-910. doi: 10.1016/j.jchf.2019.08.001. Epub 2019 Sep 11. JACC Heart Fail. 2019. PMID: 31521688 Review. No abstract available.
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
DeFilippis EM, Butler J, Vaduganathan M. DeFilippis EM, et al. Circ Heart Fail. 2017 Nov;10(11):e004478. doi: 10.1161/CIRCHEARTFAILURE.117.004478. Circ Heart Fail. 2017. PMID: 29138249 Free PMC article. No abstract available.
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Böhm M, Chioncel O, Filippatos G, Jankowska EA, Lopatin Y, Lund L, Milicic D, Moura B, Ben Gal T, Ristic A, Rakisheva A, Savarese G, Mullens W, Piepoli M, Bayes-Genis A, Thum T, Anker SD, Seferovic P, Coats AJS. Abdelhamid M, et al. Eur J Heart Fail. 2022 Sep;24(9):1460-1466. doi: 10.1002/ejhf.2594. Epub 2022 Jul 16. Eur J Heart Fail. 2022. PMID: 35753058 Review.
Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
Packer M. Packer M. Circ Arrhythm Electrophysiol. 2019 Jun;12(6):e007430. doi: 10.1161/CIRCEP.119.007430. Epub 2019 Jun 4. Circ Arrhythm Electrophysiol. 2019. PMID: 31159583 Review. No abstract available.
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS, Kunze KL, Lee JZ, Amin M, Neville MR, Almader-Douglas D, Killu AM, Madhavan M, Cha YM, Asirvatham SJ, Friedman PA, Gersh BJ, Mulpuru SK. Tseng AS, et al. Circ Arrhythm Electrophysiol. 2019 Jun;12(6):e006951. doi: 10.1161/CIRCEP.118.006951. Epub 2019 Jun 4. Circ Arrhythm Electrophysiol. 2019. PMID: 31159582

See all similar articles

Cited by

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction.
Fernandes ADF, Fernandes GC, Ternes CMP, Cardoso R, Chaparro SV, Goldberger JJ. Fernandes ADF, et al. Heart Rhythm O2. 2021 Dec 17;2(6Part B):724-732. doi: 10.1016/j.hroo.2021.09.009. eCollection 2021 Dec. Heart Rhythm O2. 2021. PMID: 34988523 Free PMC article.
Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials.
Gao J, Zhao C, Zhang WZ, Liu S, Xin H, Lian ZX. Gao J, et al. Heart Fail Rev. 2023 Jul;28(4):905-923. doi: 10.1007/s10741-022-10273-3. Epub 2022 Oct 3. Heart Fail Rev. 2023. PMID: 36184714 Free PMC article.
The Impact of Angiotensin Receptor-Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis.
Mujadzic H, Prousi GS, Napier R, Siddique S, Zaman N. Mujadzic H, et al. J Innov Card Rhythm Manag. 2022 Sep 15;13(9):5164-5175. doi: 10.19102/icrm.2022.130905. eCollection 2022 Sep. J Innov Card Rhythm Manag. 2022. PMID: 36196235 Free PMC article. Review.
Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial.
Packer M. Packer M. Eur Heart J. 2022 Nov 1;43(41):4374-4377. doi: 10.1093/eurheartj/ehac399. Eur Heart J. 2022. PMID: 35900836 Free PMC article.
Cardiovascular magnetic resonance left ventricular 4D-flow: differences in flow components and kinetic energy across heart failure spectrum.
Wong HW, Wang H, Kwan CT, Wong EK, Xu Y, Leung KH, Biekan J, Jang J, Yiu KH, Tse HF, Janich MA, Montero D, Yan AT, Ferreira VM, Ng MY. Wong HW, et al. Eur Heart J Imaging Methods Pract. 2025 May 14;3(1):qyaf059. doi: 10.1093/ehjimp/qyaf059. eCollection 2025 Jan. Eur Heart J Imaging Methods Pract. 2025. PMID: 40433564 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information